Peringatan Keamanan

Oral, mouse: LD50 = 987 mg/kg; Oral, rabbit: LD50 = 2500 mg/kg; Oral, rat: LD50 = 1600 mg/kg

Phenacemide

DB01121

small molecule approved

Deskripsi

Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.

Struktur Molekul 2D

Berat 178.1879
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 22-25 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Almost completely absorbed.

Metabolisme

Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. Co-administration with food may reduce gastrointestinal upset.

Interaksi Obat

809 Data
Buprenorphine Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Hydrocodone Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Magnesium sulfate The therapeutic efficacy of Phenacemide can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Phenacemide may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Mirtazapine Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Orphenadrine Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Pramipexole Phenacemide may increase the sedative activities of Pramipexole.
Ropinirole Phenacemide may increase the sedative activities of Ropinirole.
Rotigotine Phenacemide may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Phenacemide.
Sodium oxybate Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Thalidomide Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Phenacemide can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Phenacemide can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Phenacemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Phenacemide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Phenacemide.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenacemide.
Ethanol Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Fluvoxamine The risk or severity of adverse effects can be increased when Phenacemide is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Phenacemide is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Phenacemide is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Phenacemide is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Phenacemide is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Phenacemide is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Phenacemide is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Phenacemide is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Phenacemide is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Phenacemide is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Phenacemide is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Phenacemide is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Phenacemide is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Phenacemide is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Phenacemide is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Phenacemide is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Phenacemide is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Phenacemide.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Phenacemide.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Phenacemide.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Phenacemide.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Phenacemide.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Phenacemide.
Cocaine The risk or severity of methemoglobinemia can be increased when Phenacemide is combined with Cocaine.
Quinidine The therapeutic efficacy of Phenacemide can be decreased when used in combination with Quinidine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Phenacemide.
Doxepin The risk or severity of CNS depression can be increased when Phenacemide is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Phenacemide is combined with Desipramine.
Pizotifen The risk or severity of CNS depression can be increased when Phenacemide is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Phenacemide is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Phenacemide is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Phenacemide.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Phenacemide.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Phenacemide.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Phenacemide.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Phenacemide.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Phenacemide.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Phenacemide.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Phenacemide.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Phenacemide.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Phenacemide.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Phenacemide.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Phenacemide.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Phenacemide.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Phenacemide.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Phenacemide.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Phenacemide.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Phenacemide.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Phenacemide.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Phenacemide.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Phenacemide.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Phenacemide.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Phenacemide.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Phenacemide.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Phenacemide.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Phenacemide.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Phenacemide.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Phenacemide.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Phenacemide.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Phenacemide.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Phenacemide.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Phenacemide.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Phenacemide.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Phenacemide.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Phenacemide.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Phenacemide.

Target Protein

Sodium channel protein type 1 subunit alpha SCN1A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3508693
    Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2.
  • PMID: 3683877
    Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Phenurone

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul